Epizyme Appoints Peter Ho, M.D., Ph.D., As Chief Development Officer And Michael Shih, J.D., As Vice President, Business Development
Epizyme, Inc. (NASDAQ:EPZM), a clinical stage biopharmaceutical company creating innovative personalized therapeutics for patients with genetically defined cancers, announced today the appointments of Peter Ho, M.D., Ph.D., as Chief Development Officer and Michael Shih, J.D. as Vice President, Business Development.
Help employers find you! Check out all the jobs and post your resume.